Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion.
暂无分享,去创建一个
J. Gribben | A. Freedman | J. Griffin | L. Nadler | M. Barber | J D Griffin | J G Gribben | L M Nadler | L. Saporito | A S Freedman | K W Blake | L Saporito | M Barber | R M Edwards | K. Blake | L. Nadler | R. Edwards | James D. Griffin | Michael Barber | John G. Gribben | Laura Saporito | Regina M. Edwards | J. D. Griffin
[1] J. Ritz,et al. In vitro regulation of human hematopoiesis by natural killer cells: analysis at a clonal level. , 1987, Blood.
[2] T. Borsós,et al. Effect of inhibiting DNA, RNA, and protein synthesis of tumor cells on their susceptibility to killing by antibody and complement. , 1977, Cancer Research.
[3] M. Oken,et al. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. , 1989, The New England journal of medicine.
[4] M. Cleary,et al. Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. , 1991, Blood.
[5] J. Ultmann,et al. Bone marrow involvement in non‐Hodgkin's lymphoma. Implications for staging and therapy , 1976, Cancer.
[6] J. Kersey,et al. Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells. , 1987, Blood.
[7] K. Anderson,et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. , 1987, The New England journal of medicine.
[8] L. Nadler,et al. A monoclonal antibody defining a lymphoma-associated antigen in man. , 1980, Journal of immunology.
[9] J. Ritz,et al. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. , 1981, The Journal of clinical investigation.
[10] J. Gribben,et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. , 1991, Blood.
[11] A. Gee,et al. Evidence for an anticomplementary factor associated with human bone marrow cells. , 1985, Journal of the National Cancer Institute.
[12] J. Gribben,et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. , 1991, The New England journal of medicine.
[13] W. Velasquez,et al. The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. , 1987, Blood.
[14] M. Cleary,et al. Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. , 1989, Blood.
[15] T. Borsós,et al. Lysis of hapten-labeled cells by anti-hapten IgG and complement: effect of cell surface hapten density. , 1982, Journal of immunology.
[16] R. R. Howe,et al. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. , 1982, The New England journal of medicine.
[17] B. Yeap,et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] E J Freireich,et al. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. , 1987, Science.
[19] S. Korsmeyer,et al. Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[20] C. Bloomfield,et al. Incidence, cytology, and histopathology of non‐Hodgkin's lymphomas in the bone marrow , 1974, Cancer.
[21] C. Bloomfield,et al. Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment. , 1988, The American journal of medicine.
[22] A. Freedman,et al. B5, a new B cell-restricted activation antigen. , 1985, Journal of immunology.
[23] G. Marti,et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. , 1983, Journal of immunology.
[24] T. Borsós,et al. Identification of lipids associated with the ability of tumor cells to resist humoral immune attack. , 1978, Journal of immunology.